Cellectis S.A. (CLLS) has released an update.
Cellectis S.A., a clinical-stage biotech firm, has announced its participation in the upcoming ASGCT Annual Meeting with two poster presentations highlighting advancements in gene-editing techniques. The presentations will cover novel TALEN editing processes that enhance gene correction and gene insertion in hematopoietic stem and progenitor cells, as well as an innovative promoter-less intron editing strategy that allows for lineage-specific expression of therapeutic genes.
For further insights into CLLS stock, check out TipRanks’ Stock Analysis page.
